Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
50.70
+0.30 (0.60%)
Aug 1, 2025, 5:35 PM CET
Recordati Industria Chimica e Farmaceutica Employees
As of December 31, 2024, Recordati Industria Chimica e Farmaceutica had 4,583 total employees, including 4,495 full-time and 88 part-time employees. The number of employees increased by 128 or 2.87% compared to the previous year.
Employees
4,583
Change (1Y)
128
Growth (1Y)
2.87%
Revenue / Employee
€557,244
Profits / Employee
€91,519
Market Cap
10.46B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,583 | 128 | 2.87% |
Dec 31, 2023 | 4,455 | 86 | 1.97% |
Dec 31, 2022 | 4,369 | 66 | 1.53% |
Dec 31, 2021 | 4,303 | -183 | -4.08% |
Dec 31, 2020 | 4,486 | 163 | 3.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
DiaSorin | 3,308 |
Amplifon | 15,070 |
EL.En. | 2,080 |
Philogen | 183 |
Safilo Group | 3,645 |
Pharmanutra | 118 |
GPI S.p.A. | 7,656 |
Garofalo Health Care | 2,708 |
Recordati Industria Chimica e Farmaceutica News
- 3 days ago - Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership - Seeking Alpha
- 3 days ago - Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs - Reuters
- 10 days ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 5 weeks ago - Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Benzinga
- 5 weeks ago - Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges - Benzinga
- 5 weeks ago - Amarin inks licensing deal with Recordati for lead drug Vazkepa - Seeking Alpha
- 3 months ago - Recordati reports Q1 results - Seeking Alpha
- 3 months ago - RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% - GlobeNewsWire